ArticleTransfusion medicine (Oxford, England)2026
Cryoprecipitate utilisation, shortages and institutional policies in the United States: A survey of practices and policies.
Article in Transfusion medicine (Oxford, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSince the COVID-19 pandemic, demand for blood products has remained high, while donations have declined. Institutional policies guiding the use of these products may affect their availability, utilisation and waste. We surveyed blood banks (BBs) in the United States (U.S.) to assess policies and practices related to cryoprecipitate compatibility and to characterise experiences with administration, shortages and waste.
methodsAn 11-question online survey was distributed to U.S. BBs via Qualtrics. Responses were exported to Excel and analysed using descriptive statistics. Variables are reported as frequencies and percentages.
resultsOf 241 BBs, 82 responded (34%). Thirty-seven (45%) served community hospitals, 31 (38%) served academic hospitals and 55 (69%) served both adult and paediatric populations. Thirty (38%) BBs reported preferentially administering ABO type-specific cryoprecipitate when available, although none reported restricting transfusion exclusively to type-specific units under all circumstances. Eighteen (23%) limited the number of out-of-group units per patient within 24 h. Ten (13%) BBs reported shortages occurring at least 3-5 times per year. During shortages, 25 (61%) BBs proactively screened orders, and 14 (34%) used fibrinogen concentrate as an alternative. Annual wastage varied, with 12 (15%) BBs discarding more than 50 pooled units, often because unused units were thawed for massive transfusion protocols (MTPs). Strategies to reduce wastage included thawing units later in the MTP cycle, proactive order screening and supplementation with fibrinogen concentrate.
conclusionAlthough a subset of BBs reported substantial shortages of cryoprecipitate, some institutions reported significant waste. Targeted strategies, such as limiting units administered, proactively reviewing orders, offering alternative products and modifying thawing policies for MTPs, may improve efficiency and reduce waste.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.